Critical Illness Insurance in Hong Kong: Frequently Asked Questions

A lump sum when the insured is diagnosed with a condition that is listed in the policy and meets every element of the policy's definition, or undergoes a specified surgery. The disease name alone is not enough; the Insurance Complaints Bureau's Complaints Panel restated in 2024 and 2025 that all requirements of the listed condition must be satisfied.

Critical illness cover pays a fixed lump sum with no restriction on use; medical insurance reimburses actual medical expenses. The Insurance Authority's 2024 leaflet says the two are not substitutes: hospital bills belong to medical insurance, lost income and recovery costs to critical illness cover.

Not necessarily. The HKFI says its 21 standardized definitions account for about 90% of claims. What matters is how tightly the core conditions (cancer, heart attack, stroke) are defined and how early-stage benefits are paid, not the headline count.

Because the definitions differ. An August 2024 comparison of six insurers found stroke definitions requiring neurological deficit lasting at least four weeks at one insurer and six weeks at another, with different exclusions (migraine; accident, injury or infection; asymptomatic strokes seen only on imaging).

The HKFI Best Practice on Standardization of Critical Illness Definitions, published March 2026 and effective 1 September 2026, standardizes bilingual definitions for 16 major and 5 minor conditions plus "Activities of Daily Living". It is voluntary; participating insurers display a Q-mark; it applies to new individual products; it will be reviewed every two to three years.

No. The HKFI states that policies are binding contracts, existing policies (individual, group or rider) are unaffected, insurers may not substitute the standardized definitions unilaterally, and renewals and reinstated policies keep their original terms. Insurers may choose to adopt the new definitions at renewal or on an increase in cover.

An advance of a percentage of the sum insured, commonly 20% to 25% in published product documents and up to 35% in some, deducted from total cover. Carcinoma-in-situ and coronary angioplasty are often claimable twice.

The theoretical maximum total payout across condition groups over the insured's lifetime, subject to each claim meeting its definition, the interval between claims and age limits. A published example allows three cancer claims totalling 300% and 700% across all groups. It is not seven times in one payment.

Depends on the wording. Published examples require a new cancer, or a recurrence, spread or continuation of the earlier cancer, with active treatment (surgery, radiotherapy, chemotherapy, targeted or immunotherapy) in the preceding period and an interval since the last diagnosis.

Commonly 90 days from the policy effective date in published term products; the Insurance Authority notes some conditions may carry longer waiting periods, up to a year. Conditions directly caused by an accident and diagnosed within the period are usually exempt. Reinstatement restarts the clock.

The number of days the insured must survive after diagnosis or surgery before the benefit is payable, commonly 14 to 30 days; some products have none and require only that the insured was alive at diagnosis. It exists to avoid overlap with death benefit.

All material facts: anything a prudent underwriter would consider in accepting the risk or setting premium and terms, including facts you could reasonably be expected to know. Material non-disclosure lets the insurer avoid the policy. The Complaints Panel's three-part test (material, known, reasonably expected to be disclosed) does not require the fact to relate to the illness claimed: a 2024-25 case with undisclosed thyroid nodules and a later breast cancer claim of about HK$530,000 was upheld for the insurer.

Re-declare in writing to the insurer so it can re-underwrite. In a 2024-25 case the Panel awarded HK$1,200,000 to a policyholder who had proactively re-declared on the issue date that a liver record belonged to her father.

Usually not. Published product documents state that standard premium rates are not guaranteed and may change with claims and renewal experience; premiums also step up by age band. Ask for the premium table for the whole term.

Diagnosis not meeting the definition, and non-disclosure. Of 75 critical illness claim disputes closed by the Insurance Complaints Bureau in 2025, 52 concerned application of policy terms, 19 non-disclosure, 3 exclusions and 1 amount of indemnity.

Appeal to the insurer first and obtain its final decision; then lodge a written complaint with the Insurance Complaints Bureau within six months (free; jurisdiction limit HK$1.5 million since 1 January 2025; Panel rulings bind member insurers); the courts remain available. In 2025 the Panel ruled for complainants in 11 of 56 adjudicated cases.

Yes, provided the entire sales process and all signatures take place in Hong Kong with a Hong Kong licensed intermediary, and the Important Facts Statement for Mainland Policyholders (IFS-MP, since 1 September 2016) is signed. Sales conducted in the Mainland fall outside Hong Kong regulation. Hong Kong has no statutory two-year incontestability rule, so disclosure obligations are more enduring than under Mainland insurance law; Mainland medical records are reviewed at claim time, and claim proceeds are paid in the policy currency. This site carries on no sales activity in Mainland China.